Back to top
more

West Pharmaceutical Services (WST)

(Delayed Data from NYSE)

$238.39 USD

238.39
488,385

-0.87 (-0.36%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $238.35 -0.04 (-0.02%) 7:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (46 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is West Pharmaceutical Services (WST) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (WST) Outperforming Other Medical Stocks This Year?

Rimmi Singhi headshot

COVID-19 Vaccine Rollout Challenges Put These Stocks in Focus

by Rimmi Singhi

With COVID-19 vaccine on the horizon, cold-chain storage stocks including TT, CARR and TMO; vial makers like GLW and WST; and logistic operators including UPS and FDX are set to hog the limelight.

Zacks Equity Research

Tivity Health's (TVTY) Shares Fall Despite Q3 Earnings Beat

by Zacks Equity Research

Tivity Health (TVTY) reports solid revenue growth in its Nutrition arm in the third quarter due to strength in Nutrisystem brand DTC.

Zacks Equity Research

Has West Pharmaceutical Services (WST) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (WST) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Owens & Minor's (OMI) Shares Fall Despite Q3 Earnings Beat

by Zacks Equity Research

Owens & Minor (OMI) reports solid revenue growth in its Global Products arm in the third quarter due to strength in PPE sales.

Zacks Equity Research

Hill-Rom (HRC) Q4 Earnings, Revenues Top Estimates, Fall Y/Y

by Zacks Equity Research

In Q3, Hill-Rom's (HRC) bed orders and backlog in the United States accelerates with sequential recovery in Patient Support Systems arm.

Zacks Equity Research

Myriad Genetics' (MYGN) Q1 Earnings & Revenues Top Estimates

by Zacks Equity Research

Myriad Genetics' (MYGN) sales in majority of the operating segments plummeted in the quarter owing to the pandemic-led business challenges.

Zacks Equity Research

National Vision (EYE) Q3 Earnings Top Estimates, Margins Up

by Zacks Equity Research

National Vision (EYE) witnesses comparable growth on increased customer transaction in Q3.

Zacks Equity Research

Tandem Diabetes (TNDM) Q3 Earnings Miss, '20 Sales View Up

by Zacks Equity Research

Tandem Diabetes' (TNDM) strong domestic pump sales and pump shipments boosted the top line.

Zacks Equity Research

CVS Health (CVS) Q3 Earnings Top Estimates, 2020 View Up

by Zacks Equity Research

CVS Health's (CVS) Q3 pharmacy claims processed rise attributable to strong net new business, partially offset by reduced new therapy prescriptions.

Zacks Equity Research

Zimmer Biomet (ZBH) Q3 Earnings Beat, Gross Margin Contracts

by Zacks Equity Research

Zimmer Biomet (ZBH) registers stronger-than-expected recovery of elective procedures in the third quarter.

Zacks Equity Research

Phibro (PAHC) Q1 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Phibro's (PAHC) core Animal Health segment, along with strength in Nutritional Specialties and Vaccines, boosted Q1 performance despite pandemic-led business disruptions.

Zacks Equity Research

Cardiovascular Systems' (CSII) Q1 Earnings Top Estimates

by Zacks Equity Research

Cardiovascular Systems (CSII) registers dismal segmental revenues despite gradual recovery in business amid the pandemic.

Zacks Equity Research

Haemonetics (HAE) Q2 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Haemonetics' (HAE) second-quarter fiscal 2021 results reflect impressive performance by Hospital segment despite dismal overall performance during the coronavirus-led crisis.

Zacks Equity Research

Novo Nordisk (NVO) Catches Eye: Stock Jumps 7.2%

by Zacks Equity Research

Novo Nordisk (NVO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Zacks Equity Research

Hologic (HOLX) Q4 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

Hologic (HOLX) exhibited robust segmental growth in fourth-quarter fiscal 2020 driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.

Zacks Equity Research

Intersect ENT (XENT) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Intersect ENT's (XENT) PROPEL implants gain momentum and recapture procedure volume in Q3 following the drop in elective sinus procedures.

Zacks Equity Research

Bruker's (BRKR) Q3 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Bruker's (BRKR) third-quarter 2020 results reflect dismal performances by two of the reporting segments and geographies due to coronavirus-led business disruptions.

Zacks Equity Research

Chemed's (CHE) Shares Up on Q3 Earnings and Revenue Beat

by Zacks Equity Research

Chemed (CHE) reports solid revenue growth across key subsidiaries in third-quarter results.

Zacks Equity Research

STERIS' (STE) Earnings & Revenues Surpass Estimates in Q2

by Zacks Equity Research

STERIS' (STE) second-quarter fiscal 2021 results reflect strong performance by the Life Sciences and the Applied Sterilization Technologies segments despite the coronavirus-led economic crisis.

Zacks Equity Research

Teleflex (TFX) Q3 Earnings & Revenues Beat, Decline Y/Y

by Zacks Equity Research

Teleflex (TFX) witnesses significant sequential improvement in segmental performance on gradual recovery of the economy.

Zacks Equity Research

Syneos Health (SYNH) Q3 Earnings Top Estimates, Margins Up

by Zacks Equity Research

Syneos Health (SYNH) registers sales decline in both its business segments due to slower recovery in reimbursable out-of-pocket expenses across both segments.

Zacks Equity Research

Illumina (ILMN) Q3 Earnings Top Estimates, Margins Decline

by Zacks Equity Research

Illumina (ILMN) exhibits dismal segmental performance in the third quarter of 2020 due to pandemic-led business disruptions.

Zacks Equity Research

NuVasive (NUVA) Q3 Earnings Beat, Gross Margin Declines

by Zacks Equity Research

NuVasive (NUVA) registers strong international performance in Q3 along with several spinal hardware product lines growing at high single digits or more.

Zacks Equity Research

ResMed (RMD) Q1 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

ResMed's (RMD) overall increase in Q1 revenues is driven by robust performance of its mask and device product portfolios on increased demand for ventilators and ventilator masks.